Related Experiment Video
Updated: Apr 21, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.2K
(E)-Labda dial-Loaded Nanoparticles for Triple Negative Breast Cancer.
Anum Munir1,2, Muhammad Rizwan3, Alan Janbey2
1Division of Natural Sciences, University of Kent, Canterbury, Kent, England.
Current Drug Targets
|April 20, 2026
Summary
This study explores (E)-labda dial-loaded nanoparticles as a novel treatment for triple-negative breast cancer (TNBC). Polymeric nanoparticles show promise for enhanced TNBC therapy, offering potential benefits over traditional chemotherapy.
Area of Science:
- Biochemistry and Nanotechnology
- Cancer Research
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is aggressive, lacking hormone receptors and targeted therapy options.
- Current chemotherapy for TNBC has limitations including toxicity, poor response rates, and high recurrence.
- There is a critical need for innovative and more effective therapeutic strategies for TNBC.
Purpose of the Study:
- To investigate the therapeutic potential of (E)-labda dial, a natural compound from Curcuma amada, formulated into nanoparticles for TNBC treatment.
- To evaluate the efficacy and safety of (E)-labda dial-loaded nanoparticles compared to traditional chemotherapy.
- To explore the interaction of (E)-labda dial with key mutant proteins in TNBC.
Main Methods:
- Whole-genome sequencing identified TNBC mutations; molecular docking and dynamics simulations assessed (E)-labda dial interactions with mutant proteins (BRCA1, BRCA2, BARD1, PALB2, TP53, CHEK2).
- Lipid-based nanoparticles (LNPs) and polymeric nanoparticles (PNPs) were developed, characterized for drug encapsulation, release kinetics, and stability.
- Cytotoxic effects were evaluated using MTT assays, and in silico pharmacokinetic models predicted treatment outcomes.
Main Results:
- Polymeric nanoparticles (PNPs) demonstrated superior encapsulation efficiency, sustained drug release, and tumor inhibition compared to LNPs.
- Molecular docking revealed stronger binding of (E)-labda dial to mutant CHEK2, BARD1, and PALB2, suggesting disruption of carcinogenic pathways.
- (E)-labda dial-loaded nanoparticles showed potential for targeted TNBC treatment with improved efficacy and reduced toxicity.
Conclusions:
- Nanoparticle formulations of (E)-labda dial represent a promising targeted therapy for TNBC, potentially overcoming limitations of conventional chemotherapy.
- This research provides a foundation for personalized and precision medicine approaches in TNBC treatment.
- Further optimization and clinical validation are necessary to establish the translational potential of these nanoparticles in practice.
